Q4/2020 12/31/2020 EPS -0.790 ZacksConsensus -0.610 ActVsEst (0.180) - Miss
Last kiniksa pharmaceuticals ltd cl a earnings: 8/12 04:02 pm
Check Earnings Report
| Impact snapshot | Event time: | KNSA | ||||
|---|---|---|---|---|---|---|
|
Last Price
|
Price Change
|
Price Change %
|
Volume Shares
|
Max Up
|
Max Down
|
Volume Ratio
%
|
Performance comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last price | ||
| VWAP | ||
|
High:
|
Max up |
High:
|
|
Low:
|
Max down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event Day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance Since Event
Time and Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
SIGN UP TODAY
Opt-in for
KNSA alerts
KNSA alerts
from News Quantified
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
KNSA alerts
High impacting Kiniksa Pharmaceuticals Ltd CL A news events
Weekly update
A roundup of the hottest topics
KNSA
News
- Kiniksa Launches Patient Registry (RESONANCE) for Recurrent PericarditisGlobeNewswire
- Kiniksa Pharmaceuticals, Ltd. (<a href="https://www.marketbeat.com/stocks/NASDAQ/KNSA/price-target/">NASDAQ: KNSA</a>) was upgraded by analysts at Zacks Investment Research from a "strong sell" rating to a "hold" rating.MarketBeat
- Kiniksa Reports Fourth Quarter and Full-Year 2020 Financial Results and Corporate and Pipeline ActivityGlobeNewswire
- Kiniksa Pharmaceuticals, Ltd. (<a href="https://www.marketbeat.com/stocks/NASDAQ/KNSA/price-target/">NASDAQ: KNSA</a>) was upgraded by analysts at Zacks Investment Research from a "sell" rating to a "hold" rating.MarketBeat
- Kiniksa Highlights Corporate Priorities and Expected 2021 MilestonesGlobeNewswire
- More
KNSA
SEC Filings
- 3/3/21 - Form 8-K
- 2/25/21 - Form S-8
- 2/25/21 - Form 10-K
- KNSA's page on the SEC website
- More